InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2023-07-10 | Daniel Goldman(D-NY10) | house | Sale | $50,001 - $100,000 |
No financial data available for DSNKY.
Company may not file with SEC or CIK is unresolved.
Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
A Look At Daiichi Sankyo Company (TSE:4568) Valuation As Oncology Pipeline Drives Undervalued Thesis
Citi sees Daiichi supply review as immaterial for AstraZeneca
Nuvation Bio (NUVB) Stock More Than Doubles Year-on-Year
5 Best Small-Cap Biotech Stocks According to Hedge Funds
Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics’ RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients
Merck’s Priority Review Cancer Drug Adds To Undervalued Growth Story
Interna Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance MNM-Based Targeted Delivery Technologies
Suntory buying Daiichi Sankyo unit for $1.3B, Nikkei reports
Nuvation Bio gains global rights to brain cancer therapy from Daiichi Sankyo
Highest and lowest quant-rated healthcare stocks above $10B cap after earnings season
Daiichi Sankyo: Hit On Multiple Fronts, But Shares Look Undervalued